CL2007002650A1 - Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras. - Google Patents
Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras.Info
- Publication number
- CL2007002650A1 CL2007002650A1 CL200702650A CL2007002650A CL2007002650A1 CL 2007002650 A1 CL2007002650 A1 CL 2007002650A1 CL 200702650 A CL200702650 A CL 200702650A CL 2007002650 A CL2007002650 A CL 2007002650A CL 2007002650 A1 CL2007002650 A1 CL 2007002650A1
- Authority
- CL
- Chile
- Prior art keywords
- hidroxiamino
- heterociclo
- useful
- pharmaceutical composition
- viral infections
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 208000036142 Viral infection Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 208000015122 neurodegenerative disease Diseases 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D333/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D333/70—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Ophthalmology & Optometry (AREA)
- Communicable Diseases (AREA)
- Transplantation (AREA)
- Virology (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US84571106P | 2006-09-19 | 2006-09-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2007002650A1 true CL2007002650A1 (es) | 2008-02-08 |
Family
ID=38974145
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL200702650A CL2007002650A1 (es) | 2006-09-19 | 2007-09-12 | Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras. |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20080214546A1 (enExample) |
| EP (1) | EP2064194B1 (enExample) |
| JP (1) | JP5432715B2 (enExample) |
| AR (1) | AR062881A1 (enExample) |
| CA (1) | CA2662773C (enExample) |
| CL (1) | CL2007002650A1 (enExample) |
| ES (1) | ES2704641T3 (enExample) |
| TW (1) | TW200819445A (enExample) |
| WO (1) | WO2008036653A2 (enExample) |
Families Citing this family (160)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003062438A1 (en) * | 2002-01-22 | 2003-07-31 | Biomatera Inc. | Method of drying biodegradable polymers |
| RS52711B (sr) | 2005-05-10 | 2013-08-30 | Incyte Corporation | Modulatori indolamin 2,3-dioksigenaze i postupci upotrebe istih |
| EP1971583B1 (en) | 2005-12-20 | 2015-03-25 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| CL2007002650A1 (es) | 2006-09-19 | 2008-02-08 | Incyte Corp | Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras. |
| WO2008036642A2 (en) * | 2006-09-19 | 2008-03-27 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| PL2315756T3 (pl) | 2008-07-08 | 2015-02-27 | Incyte Holdings Corp | 1,2,5-oksadiazole jako inhibitory 2,3-dioksygenazy indoloaminy |
| CN102558083B (zh) * | 2010-12-22 | 2015-07-01 | 无锡药明康德生物技术有限公司 | N,n-双取代-3-氨基异噁唑-5-甲醇化合物的合成方法 |
| CN102558084A (zh) * | 2010-12-22 | 2012-07-11 | 上海药明康德新药开发有限公司 | N,n-双取代-3-氨基异噁唑-5-羧酸化合物的合成方法 |
| GB201120860D0 (en) | 2011-12-05 | 2012-01-18 | Cambridge Entpr Ltd | Cancer immunotherapy |
| KR20150087400A (ko) | 2012-11-20 | 2015-07-29 | 버텍스 파마슈티칼스 인코포레이티드 | 인돌아민 2,3-디옥시게나제의 억제제로서 유용한 화합물 |
| KR102617531B1 (ko) | 2013-11-08 | 2023-12-27 | 인사이트 홀딩스 코포레이션 | 인돌아민 2,3-디옥시게나제 억제제의 합성 방법 |
| DK3466949T3 (da) | 2013-12-24 | 2021-03-15 | Bristol Myers Squibb Co | Tricyklisk forbindelse som anticancermidler |
| CA2951259A1 (en) * | 2014-06-06 | 2015-12-10 | Flexus Biosciences, Inc. | Immunoregulatory agents |
| JP6449338B2 (ja) | 2014-06-06 | 2019-01-09 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | グルココルチコイド誘導腫瘍壊死因子受容体（ｇｉｔｒ）に対する抗体およびその使用 |
| HUE050596T2 (hu) | 2014-11-21 | 2020-12-28 | Bristol Myers Squibb Co | Antitestek CD73 ellen és azok felhasználásai |
| US10525035B2 (en) | 2014-12-18 | 2020-01-07 | Lankenau Institute For Medical Research | Methods and compositions for the treatment of retinopathy and other ocular diseases |
| TW201630907A (zh) | 2014-12-22 | 2016-09-01 | 必治妥美雅史谷比公司 | ＴＧＦβＲ拮抗劑 |
| AR103268A1 (es) | 2014-12-23 | 2017-04-26 | Bristol Myers Squibb Co | Anticuerpos contra tigit |
| WO2016127052A1 (en) | 2015-02-05 | 2016-08-11 | Bristol-Myers Squibb Company | Cxcl11 and smica as predictive biomarkers for efficacy of anti-ctla4 immunotherapy |
| EA037112B1 (ru) | 2015-03-02 | 2021-02-08 | Ригель Фармасьютикалс, Инк. | Ингибиторы tgf- |
| AU2016242978A1 (en) | 2015-04-03 | 2017-11-23 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase for the treatment of cancer |
| TW201642897A (zh) | 2015-04-08 | 2016-12-16 | Ｆ 星生物科技有限公司 | Ｈｅｒ２結合劑治療 |
| CN107709365A (zh) | 2015-04-13 | 2018-02-16 | 戊瑞治疗有限公司 | 癌症组合疗法 |
| WO2016183114A1 (en) | 2015-05-11 | 2016-11-17 | Bristol-Myers Squibb Company | Tricyclic compounds as anticancer agents |
| US9725449B2 (en) | 2015-05-12 | 2017-08-08 | Bristol-Myers Squibb Company | Tricyclic compounds as anticancer agents |
| ES2770349T3 (es) | 2015-05-12 | 2020-07-01 | Bristol Myers Squibb Co | Compuestos de 5H-pirido[3,2-b]indol como agentes antineoplásicos |
| UY36687A (es) | 2015-05-29 | 2016-11-30 | Bristol Myers Squibb Company Una Corporación Del Estado De Delaware | Anticuerpos contra ox40 y sus usos |
| KR20180021833A (ko) | 2015-06-29 | 2018-03-05 | 더 락커펠러 유니버시티 | 증진된 효능제 활성을 갖는 cd40에 대한 항체 |
| KR20180034548A (ko) | 2015-07-28 | 2018-04-04 | 브리스톨-마이어스 스큅 컴퍼니 | Tgf 베타 수용체 길항제 |
| US20180250303A1 (en) | 2015-08-25 | 2018-09-06 | Bristol-Myers Squibb Company | Tgf beta receptor antagonists |
| CA3001131A1 (en) | 2015-11-02 | 2017-05-11 | Five Prime Therapeutics, Inc. | Cd80 extracellular domain polypeptides and their use in cancer treatment |
| CN108738324B (zh) | 2015-11-19 | 2022-06-21 | 百时美施贵宝公司 | 抗糖皮质激素诱导的肿瘤坏死因子受体(gitr)抗体及其用途 |
| JP7349787B2 (ja) | 2015-11-23 | 2023-09-25 | ファイヴ プライム セラピューティクス インク | 癌治療におけるｆｇｆｒ２阻害剤単独または免疫刺激剤との組み合わせ |
| JP6856648B2 (ja) | 2015-12-15 | 2021-04-07 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｃｘｃｒ４受容体アンタゴニスト |
| JP7066186B2 (ja) | 2016-02-19 | 2022-05-13 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 肥満の処置のための方法及び医薬組成物 |
| RU2638530C2 (ru) * | 2016-02-29 | 2017-12-14 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) | ПРОИЗВОДНЫЕ 5-АМИНОИЗОКСАЗОЛА - КОНФОРМАЦИОННО-ЖЕСТКИЕ АНАЛОГИ γ-АМИНОМАСЛЯНОЙ КИСЛОТЫ И СПОСОБ ИХ ПОЛУЧЕНИЯ |
| IL295230A (en) | 2016-03-04 | 2022-10-01 | Bristol Myers Squibb Co | Combination therapy with anti-cd73 antibodies |
| KR102414558B1 (ko) | 2016-04-18 | 2022-06-29 | 셀덱스 쎄라퓨틱스, 인크. | 인간 cd40에 결합하는 효능성 항체 및 이의 용도 |
| US10544099B2 (en) | 2016-05-04 | 2020-01-28 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
| KR20190004742A (ko) | 2016-05-04 | 2019-01-14 | 브리스톨-마이어스 스큅 컴퍼니 | 인돌아민 2,3-디옥시게나제의 억제제 및 그의 사용 방법 |
| JP2019522627A (ja) | 2016-05-04 | 2019-08-15 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | インドールアミン２，３−ジオキシゲナーゼ阻害剤およびその使用方法 |
| JP2019516682A (ja) | 2016-05-04 | 2019-06-20 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | インドールアミン２，３−ジオキシゲナーゼ阻害剤およびその使用方法 |
| EP3452452A4 (en) | 2016-05-04 | 2019-10-30 | Bristol-Myers Squibb Company | INHIBITORS OF INDOLEAMINE-2,3-DIOXYGENASE AND METHOD FOR THEIR USE |
| JP7027401B2 (ja) | 2016-07-14 | 2022-03-01 | ブリストル－マイヤーズ スクイブ カンパニー | Ｔｉｍ３に対する抗体およびその使用 |
| WO2018017633A1 (en) | 2016-07-21 | 2018-01-25 | Bristol-Myers Squibb Company | TGF Beta RECEPTOR ANTAGONISTS |
| EP3503916A1 (en) | 2016-08-26 | 2019-07-03 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
| UY37466A (es) | 2016-11-03 | 2018-01-31 | Phenex Discovery Verwaltungs Gmbh | N-hidroxiamidinheterociclos sustituidos como moduladores de la indolamina 2,3-dioxigenasa |
| NZ754364A (en) | 2016-12-22 | 2023-04-28 | Calithera Biosciences Inc | Compositions and methods for inhibiting arginase activity |
| WO2018132279A1 (en) | 2017-01-05 | 2018-07-19 | Bristol-Myers Squibb Company | Tgf beta receptor antagonists |
| CA3047002A1 (en) | 2017-01-17 | 2018-07-26 | Board Of Regents, The University Of Texas System | Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase |
| AU2018243640A1 (en) | 2017-03-29 | 2019-09-12 | Merck Sharp & Dohme Corp. | Novel substituted N'-hydroxycarbamimidoyl-1,2,5-oxadiazole compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors |
| CA3057687A1 (en) | 2017-03-31 | 2018-10-04 | Five Prime Therapeutics, Inc. | Combination therapy for cancer using anti-gitr antibodies |
| TWI788340B (zh) | 2017-04-07 | 2023-01-01 | 美商必治妥美雅史谷比公司 | 抗icos促效劑抗體及其用途 |
| TWI778050B (zh) | 2017-04-21 | 2022-09-21 | 美商醫肯納腫瘤學公司 | 吲哚ahr抑制劑及其用途 |
| CA3057866A1 (en) | 2017-04-28 | 2018-11-01 | Five Prime Therapeutics, Inc. | Methods of treatment with cd80 extracellular domain polypeptides |
| US11066392B2 (en) | 2017-05-12 | 2021-07-20 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
| US11236049B2 (en) | 2017-06-30 | 2022-02-01 | Bristol-Myers Squibb Company | Amorphous and crystalline forms of IDO inhibitors |
| RU2658837C1 (ru) * | 2017-06-30 | 2018-06-25 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) | Способ получения 5-аминоизоксазолкарбоновой кислоты |
| EP3658565B1 (en) | 2017-07-28 | 2022-11-09 | Bristol-Myers Squibb Company | Cyclic dinucleotides as anticancer agents |
| MX2020001793A (es) | 2017-08-17 | 2020-07-22 | Ikena Oncology Inc | Inhibidores del receptor de hidrocarburos de arilo (ahr) y usos de los mismos. |
| JP7208225B2 (ja) | 2017-08-31 | 2023-01-18 | ブリストル－マイヤーズ スクイブ カンパニー | 抗癌剤としての環状ジヌクレオチド |
| WO2019046498A1 (en) | 2017-08-31 | 2019-03-07 | Bristol-Myers Squibb Company | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS |
| WO2019046496A1 (en) | 2017-08-31 | 2019-03-07 | Bristol-Myers Squibb Company | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS |
| ES2935729T3 (es) | 2017-09-14 | 2023-03-09 | Lankenau Inst Medical Res | Métodos y composiciones para el tratamiento del cáncer |
| US11203592B2 (en) | 2017-10-09 | 2021-12-21 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
| US11649212B2 (en) | 2017-10-09 | 2023-05-16 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
| EP3694552A1 (en) | 2017-10-10 | 2020-08-19 | Tilos Therapeutics, Inc. | Anti-lap antibodies and uses thereof |
| WO2019074887A1 (en) | 2017-10-10 | 2019-04-18 | Bristol-Myers Squibb Company | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS |
| KR102747388B1 (ko) | 2017-10-16 | 2024-12-26 | 브리스톨-마이어스 스큅 컴퍼니 | 항암제로서의 시클릭 디뉴클레오티드 |
| JP2021501801A (ja) | 2017-11-01 | 2021-01-21 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 癌の処置に用いるための免疫刺激アゴニスト抗体 |
| KR102808367B1 (ko) | 2017-11-06 | 2025-05-14 | 브리스톨-마이어스 스큅 컴퍼니 | Hpk1 억제제로서 유용한 이소푸라논 화합물 |
| EP3724177A1 (en) | 2017-12-12 | 2020-10-21 | Phenex Discovery Verwaltungs-GmbH | Oxalamides as modulators of indoleamine 2,3-dioxygenase |
| CN111788227B (zh) | 2017-12-27 | 2025-02-25 | 百时美施贵宝公司 | 抗cd40抗体及其用途 |
| US11447449B2 (en) | 2018-01-05 | 2022-09-20 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
| KR20250078626A (ko) | 2018-01-12 | 2025-06-02 | 브리스톨-마이어스 스큅 컴퍼니 | Tim3에 대한 항체 및 그의 용도 |
| US10519187B2 (en) | 2018-02-13 | 2019-12-31 | Bristol-Myers Squibb Company | Cyclic dinucleotides as anticancer agents |
| WO2019173587A1 (en) | 2018-03-08 | 2019-09-12 | Bristol-Myers Squibb Company | Cyclic dinucleotides as anticancer agents |
| PE20210290A1 (es) | 2018-03-21 | 2021-02-11 | Five Prime Therapeutics Inc | ANTICUERPOS DE UNION A VISTA A pH ACIDO |
| BR112020018539A2 (pt) | 2018-03-23 | 2020-12-29 | Bristol-Myers Squibb Company | Anticorpos contra mica e/ou micb e usos dos mesmos |
| EP3774755B1 (en) | 2018-03-29 | 2022-05-18 | Phenex Discovery Verwaltungs-GmbH | Spirocyclic compounds as modulators of indoleamine 2,3-dioxygenase |
| MX2020010604A (es) | 2018-04-12 | 2020-10-20 | Bristol Myers Squibb Co | Terapia de combinacion anticancer con anticuerpo antagonista del grupo de diferenciacion 73 (cd73) y anticuerpo antagonista del eje proteina de muerte programada 1 (pd-1)/ligando de muerte programada 1 (pd-l1). |
| US10973834B2 (en) | 2018-04-16 | 2021-04-13 | Arrys Therapeutics, Inc. | EP4 inhibitors and use thereof |
| WO2019206800A1 (en) | 2018-04-24 | 2019-10-31 | Phenex Discovery Verwaltungs-GmbH | Spirocyclic compounds as modulators of indoleamine 2,3-dioxygenase |
| WO2019213340A1 (en) | 2018-05-03 | 2019-11-07 | Bristol-Myers Squibb Company | Uracil derivatives as mer-axl inhibitors |
| ES2950007T3 (es) | 2018-06-27 | 2023-10-04 | Bristol Myers Squibb Co | Compuestos de naftiridinona útiles como activadores de células T |
| HRP20231253T1 (hr) | 2018-06-27 | 2024-02-02 | Bristol-Myers Squibb Company | Supstituirani spojevi naftiridina korisni kao aktivatori t stanica |
| CA3104530A1 (en) | 2018-07-09 | 2020-01-16 | Five Prime Therapeutics, Inc. | Antibodies binding to ilt4 |
| AU2019301120A1 (en) | 2018-07-11 | 2021-02-25 | Bristol-Myers Squibb Company | Antibodies binding to VISTA at acidic pH |
| US11046649B2 (en) | 2018-07-17 | 2021-06-29 | Board Of Regents, The University Of Texas System | Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase |
| WO2020023355A1 (en) | 2018-07-23 | 2020-01-30 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
| US12145927B2 (en) | 2018-07-23 | 2024-11-19 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
| US11253525B2 (en) | 2018-08-29 | 2022-02-22 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
| US10959986B2 (en) | 2018-08-29 | 2021-03-30 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
| US11130802B2 (en) | 2018-10-10 | 2021-09-28 | Tilos Therapeutics, Inc. | Anti-lap antibody variants |
| US12152019B2 (en) | 2018-10-17 | 2024-11-26 | Merck Sharp & Dohme Llc | Arylalkyl pyrazole compounds as indoleamine 2,3-dioxygenase inhibitors |
| MY205758A (en) | 2018-11-16 | 2024-11-12 | Bristol Myers Squibb Co | Anti-nkg2a antibodies and uses thereof |
| WO2020231713A1 (en) | 2019-05-13 | 2020-11-19 | Bristol-Myers Squibb Company | AGONISTS OF ROR GAMMAt |
| WO2020231766A1 (en) | 2019-05-13 | 2020-11-19 | Bristol-Myers Squibb Company | AGONISTS OF ROR GAMMAt |
| CN111943906B (zh) * | 2019-05-14 | 2023-12-15 | 中国医学科学院药物研究所 | 脒类衍生物、及其制法和药物组合物与用途 |
| US20220306630A1 (en) | 2019-08-06 | 2022-09-29 | Bristol-Myers Squibb Company | AGONISTS OF ROR GAMMAt |
| AR119821A1 (es) | 2019-08-28 | 2022-01-12 | Bristol Myers Squibb Co | Compuestos de piridopirimidinonilo sustituidos útiles como activadores de células t |
| CA3149719A1 (en) | 2019-09-19 | 2021-03-25 | Bristol-Myers Squibb Company | Antibodies binding to vista at acidic ph |
| AR120481A1 (es) | 2019-11-19 | 2022-02-16 | Bristol Myers Squibb Co | Compuestos útiles como inhibidores de la proteína helios |
| PL4065582T3 (pl) | 2019-11-26 | 2025-08-18 | Ikena Oncology, Inc. | Polimorficzne pochodne karbazolu i ich zastosowania |
| CN115151306A (zh) | 2019-11-26 | 2022-10-04 | 百时美施贵宝公司 | (r)-n-(4-氯苯基)-2-((1s，4s)-4-(6-氟喹啉-4-基)环己基)丙酰胺的盐/共晶 |
| CN114846015B (zh) | 2019-12-23 | 2024-07-30 | 百时美施贵宝公司 | 用作t细胞激活剂的经取代的杂芳基化合物 |
| AR120823A1 (es) | 2019-12-23 | 2022-03-23 | Bristol Myers Squibb Co | Compuestos bicíclicos sustituidos útiles como activadores de células t |
| IL294269A (en) | 2019-12-23 | 2022-08-01 | Bristol Myers Squibb Co | Substituted quinolinonyl piperazine compounds useful as t cell activators |
| ES3038401T3 (en) | 2019-12-23 | 2025-10-13 | Bristol Myers Squibb Co | Substituted quinazolinyl compounds useful as t cell activators |
| CN115175907B (zh) | 2019-12-23 | 2024-08-02 | 百时美施贵宝公司 | 可用作t细胞激活剂的经取代的哌嗪衍生物 |
| WO2021141907A1 (en) | 2020-01-06 | 2021-07-15 | Hifibio (Hong Kong) Limited | Anti-tnfr2 antibody and uses thereof |
| JP7719799B2 (ja) | 2020-01-07 | 2025-08-06 | ハイファイバイオ， インコーポレイテッド | 抗ガレクチン－９抗体およびその使用 |
| CN115279771B (zh) | 2020-01-15 | 2025-03-21 | 缆图药品公司 | Map4k1抑制剂 |
| WO2021183428A1 (en) | 2020-03-09 | 2021-09-16 | Bristol-Myers Squibb Company | Antibodies to cd40 with enhanced agonist activity |
| TW202140441A (zh) | 2020-03-23 | 2021-11-01 | 美商必治妥美雅史谷比公司 | 經取代之側氧基異吲哚啉化合物 |
| EP4132971A1 (en) | 2020-04-09 | 2023-02-15 | Merck Sharp & Dohme LLC | Affinity matured anti-lap antibodies and uses thereof |
| US20230192867A1 (en) | 2020-05-15 | 2023-06-22 | Bristol-Myers Squibb Company | Antibodies to garp |
| WO2021258010A1 (en) | 2020-06-19 | 2021-12-23 | Gossamer Bio Services, Inc. | Oxime compounds useful as t cell activators |
| US20230303695A1 (en) | 2020-08-10 | 2023-09-28 | Tengfei XIAO | Compositions and methods for treating autoimmune diseases and cancers by targeting igsf8 |
| CN112521357B (zh) * | 2020-08-31 | 2021-10-08 | 深圳瑞健生物科技有限公司 | 一种长效低成瘾性hnk衍生物及其制备方法 |
| CA3198456A1 (en) | 2020-10-14 | 2022-04-21 | Five Prime Therapeutics, Inc. | Anti-c-c chemokine receptor 8 (ccr8) antibodies and methods of use thereof |
| CN116964050A (zh) | 2020-12-16 | 2023-10-27 | 戈萨默生物服务公司 | 可用作t细胞激活剂的化合物 |
| US20240109899A1 (en) | 2021-02-04 | 2024-04-04 | Bristol-Myers Squibb Company | Benzofuran compounds as sting agonists |
| PE20231505A1 (es) | 2021-02-12 | 2023-09-26 | Hoffmann La Roche | Derivados de tetrahidroazepina biciclicos para el tratamiento del cancer |
| EP4305041A1 (en) | 2021-03-08 | 2024-01-17 | Blueprint Medicines Corporation | Map4k1 inhibitors |
| US11918582B2 (en) | 2021-03-15 | 2024-03-05 | Rapt Therapeutics, Inc. | Pyrazole pyrimidine compounds and uses thereof |
| JP2024514530A (ja) | 2021-04-02 | 2024-04-02 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 切断型ｃｄｃｐ１に対する抗体およびその使用 |
| KR20230167067A (ko) | 2021-04-05 | 2023-12-07 | 브리스톨-마이어스 스큅 컴퍼니 | 암의 치료를 위한 피리디닐 치환된 옥소이소인돌린 화합물 |
| SI4320112T1 (sl) | 2021-04-06 | 2025-09-30 | Bristol-Myers Squibb Company | Oksoizoindolin spojine, substituirane s piridinilom |
| KR20240083168A (ko) | 2021-07-14 | 2024-06-11 | 블루프린트 메디신즈 코포레이션 | Map4k1 저해제로서의 헤테로사이클 화합물 |
| WO2023288264A1 (en) | 2021-07-15 | 2023-01-19 | Blueprint Medicines Corporation | Map4k1 inhibitors |
| WO2023122778A1 (en) | 2021-12-22 | 2023-06-29 | Gossamer Bio Services, Inc. | Pyridazinone derivatives useful as t cell activators |
| WO2023122772A1 (en) | 2021-12-22 | 2023-06-29 | Gossamer Bio Services, Inc. | Oxime derivatives useful as t cell activators |
| WO2023122777A1 (en) | 2021-12-22 | 2023-06-29 | Gossamer Bio Services, Inc. | Oxime derivatives useful as t cell activators |
| CN118946556A (zh) | 2022-02-01 | 2024-11-12 | 阿维纳斯运营公司 | Dgk靶向化合物及其用途 |
| WO2024036100A1 (en) | 2022-08-08 | 2024-02-15 | Bristol-Myers Squibb Company | Substituted tetrazolyl compounds useful as t cell activators |
| CN119677740A (zh) | 2022-08-09 | 2025-03-21 | 百时美施贵宝公司 | 用作t细胞活化剂的叔胺取代的双环化合物 |
| PE20251399A1 (es) | 2022-08-11 | 2025-05-22 | Hoffmann La Roche | Derivados de tetrahidrotiazepina biciclicos |
| CR20250043A (es) | 2022-08-11 | 2025-03-25 | Hoffmann La Roche | Derivados bicíclicos de tetrahidrotiazepina |
| JP2025526683A (ja) | 2022-08-11 | 2025-08-15 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | 二環式テトラヒドロチアゼピン誘導体 |
| CN119677732A (zh) | 2022-08-11 | 2025-03-21 | 豪夫迈·罗氏有限公司 | 双环四氢氮杂䓬衍生物 |
| WO2024137865A1 (en) | 2022-12-22 | 2024-06-27 | Gossamer Bio Services, Inc. | Compounds useful as t cell activators |
| GB202303250D0 (en) | 2023-03-06 | 2023-04-19 | King S College London | Method and compounds |
| PE20260451A1 (es) | 2023-05-08 | 2026-02-25 | Bristol Myers Squibb Company | Compuestos de feniloxazolona sustituida |
| WO2024233900A1 (en) | 2023-05-10 | 2024-11-14 | Blueprint Medicines Corporation | Gsk3a inhibitors and methods of use thereof |
| KR20260020409A (ko) | 2023-05-31 | 2026-02-11 | 브리스톨-마이어스 스큅 컴퍼니 | Ikzf1-4 단백질의 수준을 감소시키기 위한 치환된 옥사졸론 화합물 |
| KR20260022374A (ko) | 2023-06-07 | 2026-02-19 | 브리스톨-마이어스 스큅 컴퍼니 | 스피로시클릭 치환된 옥소이소인돌리닐 피페리딘-2,6-디온 화합물 |
| WO2024263853A1 (en) | 2023-06-23 | 2024-12-26 | Bristol-Myers Squibb Company | Substituted oxoisoindolinyl piperidine-2,6-dione compound as anticancer agent |
| WO2025030002A2 (en) | 2023-08-02 | 2025-02-06 | Arvinas Operations, Inc. | Dgk targeting compounds and uses thereof |
| JP7789280B1 (ja) | 2023-09-02 | 2025-12-19 | ブリストル－マイヤーズ スクイブ カンパニー | 置換フェニルオキソオキサゾリルピペリジンジオン化合物 |
| WO2025064197A1 (en) | 2023-09-02 | 2025-03-27 | Bristol-Myers Squibb Company | Substituted azetidinyl oxoisoindolinyl piperidine-2,6-dione compounds |
| EP4587429B1 (en) | 2023-09-13 | 2026-02-18 | Bristol-Myers Squibb Company | Substituted oxoisoindolinyl piperidine-2,6-dione compounds |
| WO2025096490A1 (en) | 2023-10-31 | 2025-05-08 | Bristol-Myers Squibb Company | Ubiquitin specific processing protease 1 (usp1) compounds |
| WO2025096494A1 (en) | 2023-10-31 | 2025-05-08 | Bristol-Myers Squibb Company | Ubiquitin specific processing protease 1 (usp1) compounds |
| WO2025096539A1 (en) | 2023-10-31 | 2025-05-08 | Bristol-Myers Squibb Company | Ubiquitin specific processing protease 1 (usp1) compounds |
| WO2025096488A1 (en) | 2023-10-31 | 2025-05-08 | Bristol-Myers Squibb Company | Ubiquitin specific processing protease 1 (usp1) compounds |
| WO2025096487A1 (en) | 2023-10-31 | 2025-05-08 | Bristol-Myers Squibb Company | Ubiquitin specific processing protease 1 (usp1) compounds |
| WO2025096505A1 (en) | 2023-10-31 | 2025-05-08 | Bristol-Myers Squibb Company | Ubiquitin specific processing protease 1 (usp1) compounds |
| WO2025226767A1 (en) | 2024-04-24 | 2025-10-30 | Bristol-Myers Squibb Company | Substituted 3-(5-(6-aminopyridin-2-yl)-4-fluoro-1-oxoisoindolin-2-yl)piperidine-2,6-dione compounds for use in the treatment of cancer |
| WO2026035787A1 (en) | 2024-08-07 | 2026-02-12 | Bristol-Myers Squibb Company | Ubiquitin specific processing protease 1 (usp1) macrocyles |
Family Cites Families (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3236855A (en) | 1964-01-17 | 1966-02-22 | Merck & Co Inc | Certain n-phenyl(thiazole-hydroxamidine) compounds and their preparation |
| US3354174A (en) | 1964-02-19 | 1967-11-21 | Sterling Drug Inc | 1-and 2-benzimidazolyl-lower-alkylamidoximes, amidines-, and guanidines |
| US3553228A (en) * | 1967-09-26 | 1971-01-05 | Colgate Palmolive Co | 3-substituted-4h(1)benzopyrano(3,4-d) isoxazoles |
| DE2040628A1 (de) | 1970-08-17 | 1972-02-24 | Fahlberg List Veb | Neue herbizide Mittel |
| US3948928A (en) * | 1972-03-17 | 1976-04-06 | Dainippon Pharmaceutical Co., Ltd. | 3-Substituted-1,2-benzisoxazoles and pharmaceutically acceptable acid addition salts thereof |
| JPS5621033B2 (enExample) * | 1973-09-05 | 1981-05-16 | ||
| FR2323683A1 (fr) | 1975-09-11 | 1977-04-08 | Philagro Sa | Nouveaux derives d'amidoximes, leur preparation et les compositions qui les contiennent |
| IE43624B1 (en) * | 1975-09-11 | 1981-04-22 | Philagro Sa | New derivatives of amidoximes |
| US4323681A (en) * | 1980-09-29 | 1982-04-06 | American Home Products Corporation | 4-Amino-2-substituted-5-pyrimidinecarboxamidoximes and carbothioamides |
| JPS58208275A (ja) | 1982-05-20 | 1983-12-03 | Lion Corp | ５−アミノ−ピラゾ−ル誘導体及び該化合物を含有する抗腫瘍剤 |
| EP0132680B1 (de) * | 1983-07-22 | 1987-01-28 | Bayer Ag | Substituierte Furazane |
| JPS60193968A (ja) | 1984-03-13 | 1985-10-02 | Toyo Jozo Co Ltd | シクロペンテン環を有するイミダゾ−ルアミドオキシムおよびその製造法 |
| JPS6259283A (ja) | 1985-09-10 | 1987-03-14 | Kaken Pharmaceut Co Ltd | セフアロスポリン化合物 |
| JP2696342B2 (ja) | 1988-06-27 | 1998-01-14 | 日本曹達株式会社 | アミジン誘導体、その製造方法及び殺ダニ剤・農園芸用殺菌剤 |
| DE68901424D1 (de) | 1988-07-05 | 1992-06-11 | Akzo Nv | Verbindungen mit bronchodilatatorischer aktivitaet. |
| JPH04297449A (ja) | 1991-03-27 | 1992-10-21 | Hokko Chem Ind Co Ltd | Ｎ−ヒドロキシベンジルグアニジン誘導体および農園芸用殺菌剤 |
| JPH05186458A (ja) | 1991-04-26 | 1993-07-27 | Japan Tobacco Inc | 新規なベンゾピラン誘導体 |
| FR2677019B1 (fr) | 1991-05-27 | 1994-11-25 | Pf Medicament | Nouvelles piperidines disubstituees-1,4, leur preparation et leur application en therapeutique. |
| JP2709677B2 (ja) | 1992-06-19 | 1998-02-04 | 株式会社大塚製薬工場 | ホスホン酸ジエステル誘導体 |
| FR2720396B1 (fr) * | 1994-05-27 | 1996-06-28 | Adir | Nouveaux N-pyridyl carboxamides et dérivés leur procédé de préparation et les compositions pharmaceutiques qui les contiennent. |
| US5731315A (en) | 1995-06-07 | 1998-03-24 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Substituted sulfonic acid n- (aminoiminomethyl)phenylalkyl!-azaheterocyclamide compounds |
| WO1997014686A1 (en) | 1995-10-17 | 1997-04-24 | Astra Pharmaceuticals Limited | Pharmaceutically active quinazoline compounds |
| AU1730497A (en) | 1996-02-17 | 1997-09-02 | Agrevo Uk Limited | Fungicidal 1,2,4-oxadiazoles and analogues |
| US5955495A (en) | 1996-05-03 | 1999-09-21 | Hoffmann-La Roche Inc. | Method of treating diseases of the CNS |
| JPH11171702A (ja) | 1997-09-24 | 1999-06-29 | Takeda Chem Ind Ltd | 害虫防除方法 |
| US6395876B1 (en) | 1997-12-05 | 2002-05-28 | Medical College Of Georgia Research Institute, Inc. | High-affinity tryptophan transporter |
| BR9813536A (pt) | 1997-12-10 | 2000-10-10 | Dainippon Ink & Chemicals | "derivados oxima e produtos quìmicos agrìcolas incluindo os mesmos" |
| BR9910912A (pt) | 1998-06-02 | 2001-03-06 | Takeda Chemical Industries Ltd | Composto, composição agroquìmica, processo para combater um inseto, e, uso do composto |
| FR2784678B1 (fr) * | 1998-09-23 | 2002-11-29 | Sod Conseils Rech Applic | Nouveaux derives de n-(iminomethyl)amines, leur preparation, leur application a titre de medicaments et les compositions pharmaceutiques les contenant |
| EP1424072A1 (en) | 1999-03-03 | 2004-06-02 | Samjin Pharmaceutical Co., Ltd. | N'-(pyridin-3-yl)-(4-phenylpiperazin-1-yl)-carboxyimidamide and -iminothiolate derivatives for the treatment of tumors |
| HK1046289A1 (zh) * | 1999-04-09 | 2003-01-03 | Abbott Gmbh & Co. Kg | 凝血酶抑制剂的前体药物 |
| NZ516111A (en) * | 1999-05-24 | 2003-05-30 | Mitsubishi Pharma Corp | Phenoxypropylamine compounds useful to treat depression |
| JP2001158785A (ja) | 1999-11-30 | 2001-06-12 | Takeda Chem Ind Ltd | 農薬組成物 |
| JP2001158786A (ja) | 1999-11-30 | 2001-06-12 | Takeda Chem Ind Ltd | 哺乳動物の外部寄生虫防除剤 |
| US6780858B2 (en) * | 2000-01-13 | 2004-08-24 | Tularik Inc. | Antibacterial agents |
| JP2001233861A (ja) | 2000-02-22 | 2001-08-28 | Ube Ind Ltd | ピラゾールオキシム化合物、その製法及び用途 |
| DE60105023T2 (de) | 2000-06-28 | 2005-08-18 | Smithkline Beecham P.L.C., Brentford | Nassvermahlungsverfahren |
| GB0108102D0 (en) * | 2001-03-30 | 2001-05-23 | Pfizer Ltd | Compounds |
| RS99503A (sr) | 2001-06-18 | 2006-12-15 | Applied Research Systems Ars Holding N.V. | Derivati pirolidin oksadiazola i tiadiazola |
| JP2005529850A (ja) * | 2002-02-19 | 2005-10-06 | ファルマシア・イタリア・エス・ピー・エー | 三環系ピラゾール誘導体、その製造方法および抗腫瘍剤としてのその使用 |
| GB0208224D0 (en) | 2002-04-10 | 2002-05-22 | Celltech R&D Ltd | Chemical compounds |
| EP1501918A4 (en) | 2002-04-12 | 2006-03-29 | Med College Georgia Res Inst | ANTIGEN PRESENTING CELL POPULATIONS AND THEIR USE AS REAGENTS TO INCREASE OR REDUCE IMMUNO TOLERANCE |
| AR039891A1 (es) | 2002-05-28 | 2005-03-09 | Dimensional Pharm Inc | Compuestos tiofen-amidinas, sus composiciones farmaceuticas y su uso para la preparacion de medicamentos para tratar enfermedades y trastornos mediados por c1s |
| US7157462B2 (en) | 2002-09-24 | 2007-01-02 | Euro-Celtique S.A. | Therapeutic agents useful for treating pain |
| US7714139B2 (en) | 2003-03-27 | 2010-05-11 | Lankenau Institute For Medcial Research | IDO inhibitors and methods of use |
| US7598287B2 (en) * | 2003-04-01 | 2009-10-06 | Medical College Of Georgia Research Institute, Inc. | Use of inhibitors of indoleamine-2,3-dioxygenase in combination with other therapeutic modalities |
| AU2004267094A1 (en) | 2003-08-20 | 2005-03-03 | Vertex Pharmaceuticals Incorporated | (4 -amino -1,2, 5-oxadiazol-4-yl) -hetxiroaromatic compounds useful as protein kinase inhibitors |
| DE10348022A1 (de) * | 2003-10-15 | 2005-05-25 | Imtm Gmbh | Neue Dipeptidylpeptidase IV-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen |
| DE10348023A1 (de) | 2003-10-15 | 2005-05-19 | Imtm Gmbh | Neue Alanyl-Aminopeptidasen-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen |
| IN2014CN03493A (enExample) * | 2004-09-08 | 2015-07-03 | Mitsubishi Tanabe Pharma Corp | |
| WO2006067532A1 (en) * | 2004-12-24 | 2006-06-29 | Prosidion Ltd | G-protein coupled receptor agonists |
| US7429667B2 (en) * | 2005-01-20 | 2008-09-30 | Ardea Biosciences, Inc. | Phenylamino isothiazole carboxamidines as MEK inhibitors |
| RS52711B (sr) | 2005-05-10 | 2013-08-30 | Incyte Corporation | Modulatori indolamin 2,3-dioksigenaze i postupci upotrebe istih |
| WO2006133417A1 (en) | 2005-06-07 | 2006-12-14 | Valeant Pharmaceuticals International | Phenylamino isothiazole carboxamidines as mek inhibitors |
| US20070038298A1 (en) | 2005-06-30 | 2007-02-15 | Sulner Joseph W | Repair of tympanic membrane using placenta derived collagen biofabric |
| DE102005060466A1 (de) | 2005-12-17 | 2007-06-28 | Bayer Cropscience Ag | Carboxamide |
| EP1971583B1 (en) | 2005-12-20 | 2015-03-25 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| WO2007095050A2 (en) * | 2006-02-09 | 2007-08-23 | Incyte Corporation | N-hydroxyguanidines as modulators of indoleamine 2,3-dioxygenase |
| JP4297449B2 (ja) | 2006-05-12 | 2009-07-15 | 株式会社サクラクレパス | 墨汁 |
| CL2007002650A1 (es) | 2006-09-19 | 2008-02-08 | Incyte Corp | Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras. |
| WO2008036643A2 (en) | 2006-09-19 | 2008-03-27 | Incyte Corporation | Amidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| US20080146624A1 (en) * | 2006-09-19 | 2008-06-19 | Incyte Corporation | Amidines as modulators of indoleamine 2,3-dioxygenase |
| WO2008036642A2 (en) | 2006-09-19 | 2008-03-27 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| WO2008058178A1 (en) | 2006-11-08 | 2008-05-15 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| CN101679297B (zh) | 2006-12-08 | 2012-01-11 | 埃克塞利希斯股份有限公司 | Lxr和fxr调节剂 |
| TW200845991A (en) * | 2007-01-12 | 2008-12-01 | Smithkline Beecham Corp | N-substituted glycine derivatives: hydroxylase inhibitors |
| US8642660B2 (en) * | 2007-12-21 | 2014-02-04 | The University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| PL2315756T3 (pl) | 2008-07-08 | 2015-02-27 | Incyte Holdings Corp | 1,2,5-oksadiazole jako inhibitory 2,3-dioksygenazy indoloaminy |
-
2007
- 2007-09-12 CL CL200702650A patent/CL2007002650A1/es unknown
- 2007-09-18 ES ES07842681T patent/ES2704641T3/es active Active
- 2007-09-18 WO PCT/US2007/078759 patent/WO2008036653A2/en not_active Ceased
- 2007-09-18 CA CA2662773A patent/CA2662773C/en active Active
- 2007-09-18 AR ARP070104118A patent/AR062881A1/es unknown
- 2007-09-18 US US11/856,982 patent/US20080214546A1/en not_active Abandoned
- 2007-09-18 JP JP2009529343A patent/JP5432715B2/ja not_active Expired - Fee Related
- 2007-09-18 EP EP07842681.4A patent/EP2064194B1/en active Active
- 2007-09-19 TW TW096135025A patent/TW200819445A/zh unknown
-
2011
- 2011-03-17 US US13/050,143 patent/US8507541B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| TW200819445A (en) | 2008-05-01 |
| EP2064194A2 (en) | 2009-06-03 |
| CA2662773A1 (en) | 2008-03-27 |
| CA2662773C (en) | 2015-11-24 |
| JP2010504347A (ja) | 2010-02-12 |
| US20110165188A1 (en) | 2011-07-07 |
| ES2704641T3 (es) | 2019-03-19 |
| US20080214546A1 (en) | 2008-09-04 |
| WO2008036653A3 (en) | 2008-07-31 |
| JP5432715B2 (ja) | 2014-03-05 |
| US8507541B2 (en) | 2013-08-13 |
| EP2064194B1 (en) | 2018-11-07 |
| AR062881A1 (es) | 2008-12-10 |
| WO2008036653A2 (en) | 2008-03-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2007002650A1 (es) | Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras. | |
| CL2008000789A1 (es) | Compuestos derivados de adenina; composicion farmaceutica que comprende a dichos compuestos, utiles para tratar enfermedades alergicas, virales o cancer, entre otras. | |
| CL2007003341A1 (es) | Compuestos derivados de imidazotriazinas; composicion farmaceutica, util para el tratamiento del cancer, arteroesclerosis y enfermedades cardiovasculares entre otras. | |
| CL2007003049A1 (es) | Compuestos derivados de 2,4-diaminopirimidina; composicion farmaceutica, utiles para tratar trastornos proliferativos. | |
| PT3415535T (pt) | Nanocorpos tm aperfeiçoados para o tratamento de distúrbios mediados por agregação | |
| CL2008000403A1 (es) | Compuestos derivados de pentafluorotiobenzamido-acetonitrilo; composicion farmaceutica; y uso para tratar una infestacion por parasitos. | |
| BRPI0816116A2 (pt) | Derivados de indol 2,3-substituídos para o tratamento de infecções virais. | |
| BRPI0819218A2 (pt) | Métodos, estojos e composições para administração de compostos farmacêuticos | |
| CL2007003226A1 (es) | Compuestos derivados de piridinona; composicion farmaceutica; y uso para tratar el cancer. | |
| CL2007003713A1 (es) | Compuestos derivados de 2-amino-4-oxo-3,5-dihidroimidazol; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar o prevenir una patologia relacionada con abeta, tales como alzheimer, parkinson, sindrome de down, entre otras | |
| WO2008115281A3 (en) | Compounds for treating viral infections | |
| CL2007003854A1 (es) | Compuestos derivados de ciclopamina; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto, util en el tratamiento de desordenes mediados por la via de hedgehog, como cancer. | |
| CL2007002693A1 (es) | Compuestos derivados de tiazol pirazolopirimidina; y composicion farmaceutica, util para el tratamiento de trastornos tales como depresion, ansiedad, obesidad e hipertension entre otras. | |
| CL2007003758A1 (es) | Compuestos derivados de aminopirimidina, inhibidores de plk1; composicion farmaceutica, util para el tratamiento de cancer. | |
| BRPI0910503A2 (pt) | compostos, composições farmacêuticas e respectivos usos. | |
| DK2131813T3 (da) | Topiske, farmaceutiske formuleringer | |
| CU20080044A7 (es) | Composiciones farmacéuticas para el tratamiento de trastornos del oído interno. | |
| CL2007003832A1 (es) | Compuestos derivados de azaespiro; procedimiento de preparacion; composicion farmaceutica; y su uso para prevenir y tratar ansiedad, trastornos depresivos, entre otras enfermedades. | |
| BRPI1012892A2 (pt) | composto, e, composição farmacêutica. | |
| BRPI0810646A2 (pt) | " compostos farmacêuticos ". | |
| CL2007002578A1 (es) | Compuestos derivados de n-(1-ftalazin-1-il-piperidin-4-il)-amidas; composicion farmaceutica; y uso para el tratamiento y prevencion de trastornos de la fertilidad, osteoporosis y cancer. | |
| CL2007002640A1 (es) | Compuestos derivados de 3-(6-oxo-1,6-dihidro-piridin-3-il)-benzamida; composicion farmaceutica; y uso en el tratamiento del cancer. | |
| CL2007002642A1 (es) | Compuestos derivados de 3-(6-oxo-1,6-dihidro-piridin-3-il)-benzamida; composicion farmaceutica; y uso en el tratamiento del cancer. | |
| CL2007002790A1 (es) | Compuestos derivados de 1h-indol y 1h-bencimidazol; composicion farmaceutica; y uso para el tratamiento de hipogonadismo, osteoporosis y cancer de prostata entre otros. | |
| WO2008127364A3 (en) | Antiviral compounds and use thereof |